of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in
female depressed patients.
Sagud M, Pivac N, Muck-Seler D, Jakovljevic M, Mihaljevic-Peles A, Korsic M.
University Hospital Center Zagreb, Department of Psychiatry, Zagreb, Croatia.
The aim of the study was to evaluate the effects of 4 and 24 weeks of
sertraline treatment (average dose 42.5 mg/day) on plasma hormone levels in 15
female patients with major depression. Baseline levels of triiodothyronine
(T(3)) were lower, while cortisol, prolactin (PRL), thyroid-stimulating hormone
(TSH), and thyroxin (T(4)) levels did not differ from the values in 16 female
controls. There was a positive correlation between the scores on the Montgomery-Asperg
Depression Rating Scale and baseline cortisol levels. Treatment with
sertraline for 4 weeks increased plasma cortisol levels, while 24
weeks of sertraline treatment increased plasma T(3) levels in depressed
patients. Neither 4, nor 24 weeks of sertraline treatment affected PRL, T(4)
and TSH levels in depressed patients. The data show different and
time-dependent effects of sertraline treatment on plasma cortisol, PRL and
thyroid hormones in female depressed patients. Copyright 2002 S. Karger AG,